打印 科室与专家门诊 妙佑医疗国际是美国规模最大、经验最丰富的医疗机构之一,在亚利桑那州、佛罗里达州和明尼苏达州都设有院区。我们的工作人员涉及数十种专业,通过齐心协力确保高品质治疗与成功康复。 有相关专长的科室 乳腺专科门诊 位于罗切斯特的乳腺及黑色素瘤肿瘤外科 妙佑医疗国际的癌症护理 杰克逊维尔院区乳腺肿瘤外科 研究 实验室技术人员正在制备用于检测的样本。 妙佑医疗国际的研究人员在推进乳腺癌精准医疗方面拥有悠久的历史。此领域的成就包括: 寻找乳腺癌的新治疗方法。 识别可以调节 DNA 修复的酶。 识别不能从芳香化酶抑制剂药物获益的乳腺癌患者亚群。 识别 CYP2D6 酶中的变异,这有助于解释为什么某些乳腺癌患者对他莫昔芬无反应。 为 CYP2D6 酶活性低的患者开发一种新药来代替他莫昔芬。 开发可耐受芳香化酶抑制剂的乳腺癌新药。 确定为什么有些人对内分泌治疗无应答的机制,然后开发一种乳腺癌新药。 妙佑医疗国际综合癌症中心是获得美国国家癌症研究所乳腺癌卓越研究专科项目(SPORE)资助的少数几家机构之一。详细了解妙佑医疗国际的乳腺癌 SPORE 项目。 文献著述请参阅美国国家医学图书馆检索服务系统 PubMed 所收录的妙佑医疗国际医生在乳腺癌领域的著述目录。 Research Profiles 编辑搜索过滤条件 close 缩小搜索范围 按位置 Arizona Florida Minnesota 观看全部 查看所有医生 • Minnesota Bakkum-Gamez, Jamie N. M.D. Minnesota Block, Matthew S. M.D., Ph.D. Minnesota Boughey, Judy C. M.D. Minnesota Cliby, Bill M.D. Minnesota Couch, Fergus J. Ph.D. Minnesota Degnim, Amy C. M.D. Minnesota Dowdy, Sean C. M.D. Minnesota Ehman, Richard L. M.D. Minnesota Goetz, Matthew P. M.D. Minnesota Goode, Ellen L. Ph.D. Minnesota Hawse, John R. IV Ph.D. Minnesota Hruska, Carrie B. Ph.D. Minnesota Jatoi, Aminah M.D. Minnesota Kannan, Nagarajan Ph.D., M.S. Minnesota Kaufmann, Scott H. M.D., Ph.D. Minnesota Khosla, Sundeep M.D. Minnesota Mariani, Andrea M.D., M.S. Minnesota Mutter, Robert W. M.D. Minnesota Oberg, Ann L. Ph.D. Minnesota Peng, Kah Whye Ph.D. Minnesota Rhodes, Deborah J. M.D. Minnesota Shridhar, Viji Ph.D. Minnesota Smith, David I. Ph.D. Minnesota Suman, Vera Ph.D. Minnesota Vachon, Celine M. Ph.D. Minnesota Walther-Antonio, Marina R. Ph.D. Minnesota Wang, Liewei M.D., Ph.D. Minnesota Weinshilboum, Richard M.D. Minnesota Weroha, John J. M.D., Ph.D. Minnesota 来自妙佑医疗国际员工 在 Mayo Clinic 治疗 申请预约 关于在 Mayo Clinic 治疗 Nov. 26, 2024 打印 显示参考文献 Jorde LB, et al., eds. Genetics and precision medicine. In: Medical Genetics. 6th ed. Elsevier; 2020. htps://www.clinicalkey.com. Accessed Dec. 21, 2023. Cyr AE, et al. Individualizing breast cancer risk assessment in clinical practice. Surgical Oncology Clinics of North America. 2023; doi:10.1016/j.soc.2023.05.013. Khan SA. Breast cancer risk reduction: Current status and emerging trends to increase efficacy and reduce toxicity of preventive medication. Surgical Oncology Clincs of North America. 2023; doi:10.1016/j.soc.2023.05.001. Reizine NM, et al. Modern developments in germline pharmacogenomics for oncology prescribing. CA: A Cancer Journal for Clinicians. 2022; doi:10.3322/caac.21722. Biomarker testing for cancer treatment. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment. Accessed Dec. 22, 2023. Liu T, et al. CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1. Nature Communications. 2017; doi:10.1038/ncomms13923. Luo K, et al. A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination. Genes & Development. 2016; doi:10.1101/gad.289439.116. Ingle JN, et al. Genetic polymorphisms in the long noncoding RNA MIR2052HG offer a pharmacogenomic basis for the response of breast cancer patients to aromatase inhibitor therapy. Cancer Research. 2016; doi:10.1158/0008-5472.CAN-16-1371. Goetz MP, et al. CYP2D6 metabolism and patient outcome in the Austrian breast and colorectal cancer study group trial (ABCSG) 8. Clinical Cancer Research. 2013; doi:10.1158/1078-0432.CCR-12-2153. Goetz MP, et al. First-in-human phase I study of the tamoxifen metabolite z-endoxifen in women with endocrine-refractory metastatic breast cancer. Journal of Clinical Oncology. 2017; doi:10.1200/JCO.2017.73.3246. D'Assoro AB, et al. The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα+ breast cancer cells. Oncogene. 2013; doi:10.1038/onc.2012.628. Ingle JN, et al. Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids. 2015; doi:10.1016/j.steroids.2014.08.007. Jayaraman S, et al. Endoxifen, an estrogen receptor targeted therapy: From bench to bedside. Endocrinology. 2021; doi:10.1210/endocr/bqab191. Goetz MP, et al. Tumor sequencing and patient-derived xenografts in the neoadjuvant treatment of breast cancer. Journal of the National Cancer Institute. 2017; doi:10.1093/jnci/djw306. Hu C, et al. Classification of BRCA2 variants of uncertain significance (VUS) using an ACMG/AMP model incorporating a homology-directed repair (HDR) functional assay. Clinical Cancer Research. 2022; doi:10.1158/1078-0432.CCR-22-0203. Couch FJ, et al. Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncology. 2017; doi:10.1001/jamaoncol.2017.0424. Precision medicine initiative cohort program biobank. NIH RePORTER. https://reporter.nih.gov/search/QPpHrqO3ekG7Z4TLi-I3RA/project-details/10489966. Accessed Nov. 15, 2023. Biobank. National Institutes of Health. https://allofus.nih.gov/funding-and-program-partners/biobank. Accessed Nov. 15, 2023. 13th conference invited speakers. International Society for Applied Biological Sciences. https://isabs.hr/13th-conference-invited-speakers. Accessed Nov. 15, 2023. Founding members. Pharmacogenomics Global Research Network. https://pgrn.org/founders. Accessed Nov. 15, 2023. Members. Personalized Medicine Coalition. https://www.personalizedmedicinecoalition.org/membership/current-members. Accessed Nov. 15, 2023. Electronic Medical Records and Genomics (eMERGE) Network. National Human Genome Research Institute. https://www.genome.gov/Funded-Programs-Projects/Electronic-Medical-Records-and-Genomics-Network-eMERGE. Accessed Nov. 15, 2023. Member institutions. Alliance for Clinical Trials in Oncology. https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FInstitutions. Accessed Nov. 15, 2023. Fowler GC, et al., eds. Pfenninger and Fowler's Procedures for Primary Care. 4th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed May 10, 2024. 相关 乳腺癌 绘制基因组信息 产品与服务 A Book: Beyond Breast Cancer 乳腺癌精准医疗关于医生与科室在 Mayo Clinic 治疗 PRC-20321688 患者护理和健康信息 医学检查与医疗程序 乳腺癌精准医疗